Market Access Biosimilars 2020 Germany

04/12/2019

The Market Access Biosimilars 2020 symposium, organised by Forum-Institut für Management, will deal with the changes in the German biosimilar market brought by the GSAV law which plans biosimilar substitution in pharmacies for 2022.

Topics include presentations of the current system of biosimilar quotas, discount contracts and capped reimbursement and their impact on launch strategy.

Speakers include representatives of HTA body G-BA, payers, doctors' associations, consultancy firm IQVIA and lawmakers.

Berlin, Germany  

More information

Ask for a Free trial and get access to the latest stories

Our coverage includes:
  • Health Care
  • Market Access
  • HTA – policies & practices
  • European medicine regulations
  • Drug safety issues
  • Pricing & Reimbursement
  • International medicines agencies

If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.

REQUEST

an initial 10 day temporary access of APM Health Europe.